Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$19.00 USD

19.00
3,994,862

-0.04 (-0.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $18.95 -0.05 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

Zacks Equity Research

Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 67.1% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.

Zacks Equity Research

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.

Zacks Equity Research

Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $20.10, marking a -0.94% move from the previous day.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed at $20.91 in the latest trading session, marking a -0.99% move from the prior day.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $21.94, moving +1.72% from the previous trading session.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $23.07, marking a -0.26% move from the previous day.